about
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidancePermanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with TookadThrombosis in multiple myelomaPhlegmasia caerulea dolens secondary to pelvic plasmacytoma and left femoral deep vein thrombosis.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies.Thromboembolic events with lenalidomide-based therapy for multiple myelomaPrevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.Pulmonary embolism as the first manifestation of multiple myeloma.Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.Screening for Malignancy in Patients With Unprovoked Venous Thromboembolism.Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.Thalidomide as anti-inflammatory therapy for multiple myeloma.Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.Aspirin as thromboprophylaxis in myeloma.Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population.Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
P2860
Q27008491-3AA29D7C-DD04-480C-9B54-FD1CE5284865Q27330438-3BE13142-8D75-4301-838C-ACD0FD7A3390Q28219961-F20001EA-8B7F-4937-A021-EC4F780204CDQ33409890-471796C4-1689-4A1E-8652-33D5E22226CEQ36381565-97A5D9D5-EF5A-4CD0-AD67-4C412255A746Q36490167-6A378E79-75B5-4B53-8C81-D727BC0976E8Q37038367-01A5F099-7797-40EE-8C20-CEC788D7D896Q37038414-47BAF990-F01A-4CE7-9A8A-832F8B6C32CFQ37212264-A0D6E26F-3784-460A-9130-0ECEA0F56325Q37364238-4C438DC3-8288-4B91-A26D-A3EBD0C8FCC3Q38230423-414CDB55-F1DD-41C6-9324-ED020A339392Q38904687-C40DB8A0-BEA0-42CC-9BDA-1303815F896FQ38921614-5BA0698F-5F13-4355-8931-B8AF9B5E785EQ44557863-01DBCFE2-9114-47D2-A93B-2BDD36AA293CQ46389744-5F562741-96E7-4DEE-AC7B-50050A13C88EQ46394264-6EB690CA-A99E-4899-A9CF-BF6EF5B805D0Q46860368-6A10838F-DF16-49F8-B28E-4D930F206227Q48235838-79548E7B-F1CE-437B-8762-800214860698Q50624082-F3ED54FB-992A-46F8-9F4D-FCFF09F7183CQ50726885-4466FE1D-1B65-4934-B6A6-770CD32BDC41Q54589521-4DD79E7F-611C-4310-A246-D66E60EF51B2
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The blood coagulation mechanism in multiple myeloma.
@ast
The blood coagulation mechanism in multiple myeloma.
@en
type
label
The blood coagulation mechanism in multiple myeloma.
@ast
The blood coagulation mechanism in multiple myeloma.
@en
prefLabel
The blood coagulation mechanism in multiple myeloma.
@ast
The blood coagulation mechanism in multiple myeloma.
@en
P2093
P356
P1476
The blood coagulation mechanism in multiple myeloma.
@en
P2093
Fariba Saghafifar
Guido Tricot
Louis Fink
Paulette Mehta
P304
P356
10.1055/S-2003-40965
P577
2003-06-01T00:00:00Z